secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2023-09-21T23:59:59+00:00
Accession:  0001600620-23-000040
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia appoints founder Dr. Foster to board; enters cooperation agreement with MKT Capital
--------------------------------------------------------------------------------

- Dr. Robert T. Foster appointed to Board effective Sept 21, 2023; term expires at 2024 Annual Meeting.
- MKT Capital agrees to standstill until Oct 31, 2024 (with conditions) and 7% ownership cap.
- Dr. Foster receives standard non-employee director compensation: $45K annual cash, $200K annual equity, $340K new director grant.
- Dr. Foster retains 2% royalty on voclosporin licensee sales and 0.3% of direct net sales ($307,254 in FY2022).
- Press release notes Dr. Foster discovered voclosporin; strategic review remains ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062023000040/0001600620-23-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062023000040/auph-20230921.htm
  HTML page:      https://secwatch.observer/filing/0001600620-23-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer